Mal-PEG5-NHS is a biomedical product that assumes a pivotal role in drug conjugation and protein modification. Its exceptional reactivity as a linker fosters targeted drug delivery, thereby ramping up therapeutic efficacy to unprecedented levels.
Structure of 1315355-92-0
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Mal-PEG5-NHS is a versatile bioconjugation reagent commonly used in the development of targeted therapies and diagnostic applications. It features a maleimide (Mal) group that allows for selective conjugation with thiol-containing molecules, such as peptides, proteins, or antibodies, and a polyethylene glycol (PEG5) spacer that enhances the solubility, stability, and bioavailability of the conjugate. The NHS (N-hydroxysuccinimide) ester is a reactive functional group that enables efficient coupling to amine groups, making this compound suitable for a wide range of applications in both therapeutic and research settings.
One of the key applications of Mal-PEG5-NHS is in the preparation of antibody-drug conjugates (ADCs) for targeted cancer therapy. The maleimide group allows the compound to conjugate to antibodies that specifically recognize tumor-associated antigens, while the PEG5 spacer improves the solubility and pharmacokinetics of the resulting conjugate. The NHS ester efficiently couples with amine-containing cytotoxic agents or small molecules, facilitating the attachment of potent drugs to the antibody. This targeted approach allows for the precise delivery of chemotherapy agents directly to the tumor, minimizing off-target effects and enhancing the therapeutic index of the treatment.
Mal-PEG5-NHS is also widely used in the design of other drug delivery systems, particularly for the development of peptide-drug conjugates or small molecule conjugates. The PEG5 spacer not only improves solubility and reduces immunogenicity but also ensures that the conjugate remains stable during circulation. The NHS ester is highly reactive with amine-containing drugs, facilitating the efficient attachment of therapeutic agents to the conjugate. This system allows for the controlled release of the drug at the disease site, making it ideal for precision medicine, where treatments can be directed specifically to target tissues such as tumors or infected cells.
In addition to drug delivery, Mal-PEG5-NHS is frequently used in diagnostic applications. It can be employed to conjugate diagnostic antibodies, peptides, or other biomolecules to imaging agents or sensors. The PEG5 spacer ensures that the conjugate maintains solubility and stability in biological environments, which is critical for maintaining effective tissue penetration and signal clarity in imaging studies. The NHS ester enables efficient conjugation to the amine-containing biomolecules, making Mal-PEG5-NHS an excellent choice for molecular imaging, biomarker detection, and diagnostics that require precise targeting of disease sites, such as cancerous tumors or inflammation.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00442 | Mal-PEG6-NHS | 1137109-21-7 | |
BADC-00448 | Mal-PEG-NHS | 1260092-50-9 | |
BADC-00450 | Mal-PEG4-NHS | 1325208-25-0 | |
BADC-01679 | Mal-PEG2-Val-Cit-PABA-PNP | 1345681-52-8 | |
BADC-00936 | Mal-PEG2-acid | 1374666-32-6 | |
BADC-00449 | Mal-PEG4-PFP | 1415800-42-8 | |
BADC-00453 | Mal-PEG2-NHS ester | 1433997-01-3 | |
BADC-00603 | Mal-PEG3-NHS ester | 1537892-36-6 | |
BADC-00966 | Mal-PEG4-VC-PAB-DMEA | 1569261-93-3 | |
BADC-00499 | Mal-PEG6-NHS ester | 1599472-25-9 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.